Volume 2, Issue 1, June 2018, Page: 1-5
Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS
Massimo Madonia, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy
Antonio Murgia, Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy; Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK
Gianmarco Garau, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy
Bruno Bussa, Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy
Pierluigi Caboni, Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
Received: May 17, 2018;       Accepted: Jun. 12, 2018;       Published: Jul. 6, 2018
DOI: 10.11648/j.ijcu.20180201.11      View  550      Downloads  36
Abstract
Renal cell carcinoma (RCC) represent 2-3% of all cancers. Currently, there are no invasive screening tests that could help to find diagnosis and possible follow up in clinical practice. Most renal tumors are diagnosed by abdominal ultrasound (US) or contrast-enhanced (CT) performed for other medical reasons. In this work, the metabolite profile of urine of RCC samples, has been studied by gas chromatography coupled to mass spectrometry (GC-MS) and multivariate statistical data analysis. By the same means, differences between pathological and control samples were investigated. Results of discriminant analysis were studied with the aim to find possible relevant metabolites for each class. Palmitic acid, malic acid, allo-inositol, oleic acid and aspartic acid were up-regulated in pathological samples while psicose was down-regulated.
Keywords
Inositol, Aspartic Acid, GC-MS, Renal Cell Cancer
To cite this article
Massimo Madonia, Antonio Murgia, Gianmarco Garau, Bruno Bussa, Pierluigi Caboni, Preliminary Metabolomic Study of Urine Samples in Patients Affected by Renal Clear Cell Cancer by GC-MS, International Journal of Clinical Urology. Vol. 2, No. 1, 2018, pp. 1-5. doi: 10.11648/j.ijcu.20180201.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2. 3, 730 entity dictionary (2001), Lyon, 2001.
[2]
Lindblad P. Epidemiology of renal cell carcinoma. Scand J Surg. 2004; 93: 88.
[3]
Eble JN, Sauter G, Epstein JI (eds). In: Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organization Classification of Tumours. Lyon: IARC Press, 2004.
[4]
Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein, JI, Grignon D et al. The International Society of Urological Pathology (ISUP) vancouver classification of renal neoplasia. The American journal of surgical pathology. 2013; 37(10): 1469-1489.
[5]
Furge KA, Tan MH, Dykema K, Kort E, Stadler W, Yao X, et al. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene. 2007; 26: 1346.
[6]
Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? EurUrol. 2010; 58: 588.
[7]
Jayson M, & Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998; 51: 203.
[8]
Hammers, H., Sternberg, C., Mcdermott, D. F., Larkin, J., Ravaud, A., Rini, B., A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus SunitinibMonotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma. 2015; p. NCT02231749.
[9]
Sim SH, Messenger MP, Gregory WM, Wind TC, Vasudev NS, Cartledge J, et al. Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer. 2012; 107: 1131.
[10]
Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J ClinOncol. 2009; 27: 2645.
[11]
Li G, Feng G, Gentil-Perret A, Genin C, Tostain J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J Urol. 2008; 180: 510.
[12]
Choueiri TK, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014; 25: 1603.
[13]
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373: 1814.
[14]
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373: 1803.
[15]
Wahlgren T, Harmenberg U, Sandström P, Lundstam S, Kowalski J, Jakobsson, M, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008). Br J Cancer. 2013; 108: 1541.
[16]
Scano P, Murgia A, Pirisi F. M, Caboni P. A gas chromatography-mass spectrometry-based metabolomic approach for the characterization of goat milk compared with cow milk. J Dairy Sci. 2014; 97(10): 6057-6066.
[17]
Pisano MB, Scano P, Murgia A, Cosentino S, Caboni P. Metabolomics and microbiological profile of Italian mozzarella cheese produced with buffalo and cow milk. Food Chem. 2016; 192: 618-624.
[18]
Dessì A, Murgia A, Agostino R, Pattumelli MG, Schirru A, Scano P, et al. Exploring the Role of Different Neonatal Nutrition Regimens during the First Week of Life by Urinary GC-MS Metabolomics. Int. J. Mol. Sci. 2016; 17(2): 265.
[19]
Eriksson L, Byrne T, Johansson E, Trygg J, Vikström C. Multi-and megavariate data analysis basic principles and applications. 2013; Umetrics Academy.
[20]
Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A. An Integrated Metabolic Atlas of Clear Cell Renal Cell. Cancer cell. 2016; 29(1): 104-116.
[21]
Schieda N, Van der Pol CB, Moosavi B, McInnes MD, Mai KT, Flood TA. Intracellular lipid in papillary renal cell carcinoma (pRCC): T2 weighted (T2W) MRI and pathologic correlation. European radiology. 2015; 25(7): 2134-2142.
[22]
Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Mimi CY. Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes & Control. 2002; 13(3): 287-293.
[23]
Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proceedings of the National Academy of Sciences. 2001; 98(6): 3387-3392.
[24]
Ooi A, Furge KA. Fumarate hydratase inactivation in renal tumors: HIF1α, NRF2, and “cryptic targets” of transcription factors. Chinese journal of cancer. 2012; 31(9): 413.
[25]
Tan J, Yu CY, Wang ZH, Chen HY, Guan J, Chen YX, et al. Genetic variants in the inositol phosphate metabolism pathway and risk of different types of cancer. Scientific reports. 2015; 5: 8473.
Browse journals by subject